CM93 / Crimson Biopharm - LARVOL DELTA

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Crimson Biopharm Inc. | Trial completion date: Jul 2028 ➔ Jul 2029 | Trial primary completion date: Jul 2027 ➔ Jul 2029

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • EGFR

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Crimson Biopharm Inc. | Trial completion date: Jul 2024 ➔ Jul 2028 | Trial primary completion date: Jul 2023 ➔ Jul 2027

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • EGFR

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) (clinicaltrials.gov) - P1; N=72; Not yet recruiting; Sponsor: Crimson Biopharm Inc.

Clinical • New P1 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • EGFR